Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 17/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 17/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 17/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 8/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 6/20 | 0.57 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.57 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7726228 | 1.00 | GABRG2 (0.61) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL3146540 | 1.00 | GABRG2 (0.61) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL8422923 | 0.91 | GABRA5 (0.62) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL8422919 | 0.91 | GABRA5 (0.62) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL8363053 | 0.89 | GABRA5 (0.61) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL13524276 | 0.89 | GABRA5 (0.61) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL8363054 | 0.88 | GABRG2 (0.61) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL8272438 | 0.88 | GABRG2 (0.61) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL7722895 | 0.88 | GABRA5 (0.77) | GABRG2GABRB3GABRA5GABRA3GABRA1 | |
| SCHEMBL7722748 | 0.88 | GABRA5 (0.77) | GABRG2GABRB3GABRA5GABRA3GABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | COOK JAMES M | 2010-01-07 | — | — | US | disclosed |
| US-7618958-B2 | Convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnosis; Ethyl 8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2009-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | CHRNA6, GABRA6, CHRNA5 | GABRG2 24/4885GABRB3 17/4885GABRA5 4/4885 |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | GABRA5, GABRA6, GABRA2 | GABRG2 11/4885GABRB3 16/4885GABRA5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.